Significance of the Expression of pAKT1 and pSyk Activation Proteins in Diffuse Large B-Cell Lymphoma

AUTOIMMUNE THROMBOCYTOPENIA ,

EV Vaneeva, VA Rosin, DA Dyakonov, SV Samarina, IV Paramonov

Kirov Research Institute of Hematology and Transfusiology, 72 Krasnoarmeiskaya ul., Kirov, Russian Federation, 610027

For correspondence: Elena Viktorovna Vaneeva, 72 Krasnoarmeiskaya ul., Kirov, Russian Federation, 610027; Tel.: +7(922)975-23-34; e-mail: vaneeva.elena.vic@mail.ru

For citation: Vaneeva EV, Rosin VA, Dyakonov DA, et al. Significance of the Expression of pAKT1 and pSyk Activation Proteins in Diffuse Large B-Cell Lymphoma. Clinical oncohematology. 2022;15(2):140–7. (In Russ).

DOI: 10.21320/2500-2139-2022-15-2-140-147

ABSTRACT

Aim. To assess the prognostic value of pAKT1 and рSyk expression in DLBCL.

Materials & Methods. The study enrolled 100 patients with newly diagnosed DLBCL treated with R-CHOP first-line immunochemotherapy. The relative count of pAKT1- and pSyk-expressing tumor cells was determined by immunohistochemical and morphometric methods. The expression cut-off of these proteins was calculated by ROC analysis. The relationship of protein expression with clinical parameters of DLBCL was analyzed by Fisher’s exact two-tailed test. The 5-year overall (OS) and progression-free (PFS) survivals were estimated by Kaplan-Meier method (log-rank test).

Results. High pAKT1 expression was associated with advanced DLBCL stages, International Prognostic Index > 2, serum lactate dehydrogenase concentration above normal, failures of R-CHOP therapy, as well as worse OS and PFS. No correlation between рSyk expression and clinical lymphoma characteristics was found. The worst 5-year OS (27.6 %) was reported in cases of pAKT1 and pSyk co-overexpression (hazard ratio [HR] 5.2; 95% confidence interval [95% CI] 2.49–10.9; p < 0.001). A similar trend was observed for PFS (HR = 3.3; 95% CI 1.54–7.30; p = 0.002).

Conclusion. Overexpression of pAKT1 is an informative indicator of a poor DLBCL prognosis. Co-overexpression of pAKT1 and рSyk markers is associated with worse OS and PFS compared to their isolated expressions and other co-expression variants.

Keywords: diffuse large B-cell lymphoma, pAKT1 and pSyk expression, overall survival, progression-free survival.

Received: November 17, 2021

Accepted: March 2, 2022

Read in PDF

Статистика Plumx английский

REFERENCES

  1. Bahar T, Chowdhury ZZ, Rahman S, et al. Clinicopathological Correlation with Outcome of Diffuse Large B Cell Lymphoma: Experience in a Specialized Cancer Care Centre in Bangladesh. J Medicine. 2021;22(1):3–6. doi: 3329/jom.v22i1.51383.
  2. Самарина С.В., Лучинин А.С., Минаева Н.В. и др. Иммуногистохимический подтип и параметры международного прогностического индекса в новой модели прогноза диффузной B-крупноклеточной лимфомы. Клиническая онкогематология. 2019;12(4):385–90. doi: 21320/2500-2139-2019-12-4-385-390.
    [Samarina SV, Luchinin AS, Minaeva NV, et al. Immunohistochemical Subtype and Parameters of International Prognostic Index in the New Prognostic Model of Diffuse Large B-Cell Lymphoma. Clinical oncohematology. 2019;12(4):385–90. doi: 10.21320/2500-2139-2019-12-4-385-390. (In Russ)]
  3. Mondello P, Mian M, Frontline treatment of diffuse large B-cell lymphoma: Beyond R‐ Hematol Oncol. 2019;37(4):333–44. doi: 10.1002/hon.2613.
  4. Song JL, Wei XL, Zhang YK, et al. The prognostic value of the international prognostic index, the national comprehensive cancer network IPI and the age-adjusted IPI in diffuse large B cell lymphoma. Zhonghua Xue Ye Xue Za Zhi. 2018;39(9):739–44. doi: 10.3760/cma.j.issn.0253-2727.2018.09.007.
  5. Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma treatment approaches in the molecular era. Nat Rev Clin Oncol. 2014;11(1):12–23. doi: 10.1038/nrclinonc.2013.197.
  6. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–11. doi: 10.1038/35000501.
  7. Расторгуев С.М., Королева Д.А., Булыгина Е.С. и др. Клиническое и прогностическое значение молекулярных маркеров диффузной В-крупноклеточной лимфомы. Клиническая онкогематология. 2019;12(1):95–100. doi: 10.21320/2500-2139-2019-12-1-95-100.
    [Rastorguev SM, Koroleva DA, Boulygina ES, et al. Clinical and Prognostic Value of Molecular Markers of Diffuse Large B-Cell Lymphoma. Clinical oncohematology. 2019;12(1):95–100. doi: 10.21320/2500-2139-2019-12-1-95-100. (In Russ)]
  8. Miao Yi, Medeiros LJ, Xu-Monette ZY, et al. Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets. Front Oncol. 2019;9:107. doi: 3389/fonc.2019.00107.
  9. Seda V, Mraz M. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells. Eur J Haematol. 2014;94(3):193–205. doi: 10.1111/ejh.12427.
  10. Никитин E.A. Передача сигнала через B-клеточный рецептор: механизмы и ингибиторы. Клиническая онкогематология. 2014;7(3):251–63.
    [Nikitin EA. B­Cell Receptor Signaling Pathway: Mechanisms and Inhibitors. Klinicheskaya onkogematologiya. 2014;7(3):251–63. (In Russ)]
  11. Wossning T, Herzog S, Kohler F, et al. Deregulated Syk inhibits differentiation and induces growth factor-independent proliferation of pre-B cells. J Exp Med. 2006;203(13):2829–40. doi: 10.1084/jem.20060967.
  12. Kumar А, Rajendran V, Sethumadhavan R, Purohit R. AKT Kinase Pathway: A Leading Target in Cancer Research. ScientificWorldJournal. 2013; 2013:756134. doi: 10.1155/2013/756134.
  13. Ванеева Е.В., Росин В.А., Дьяконов Д.А. и др. Значение экспрессии pAKT1 при диффузной В-крупноклеточной лимфоме. Бюллетень сибирской медицины. 2021;3:6–13.
    [Vaneeva EV, Rosin VA, D’yakonov DA, et al. Significance of pAKT1 expression in diffuse large B-cell lymphoma. Byulleten’ sibirskoi meditsiny. 2021;3:6–13. (In Russ)]
  14. Karmali R, Gordon LI. Molecular Subtyping in Diffuse Large B Cell Lymphoma: Closer to an Approach of Precision Therapy. Curr Treat Options Oncol. 2017;18(2):11. doi: 10.1007/s11864-017-0449-1.
  15. Wang X, Cao X, Sun R, et al. Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. Neoplasia. 2018;20(6):574–93. doi: 10.1016/j.neo.2018.03.002.
  16. Wang J, Xu-Monette ZY, Jabbar KJ, et al. AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. Am J Pathol. 2017;187(8):1700–16. doi: 10.1016/j.ajpath.2017.04.009.
  17. Hong JY, Hong ME, Choi MK, et al. The impact of activated p-AKT expression on clinical outcomes in diffuse large B-cell lymphoma: A clinicopathological study of 262 cases. Ann Oncol. 2014;25(1):182–8. doi: 10.1093/annonc/mdt530.